Precipio Inc
$ 23.70
1.28%
21 Jul - close price
- Market Cap 41,824,500 USD
- Current Price $ 23.70
- High / Low $ 24.55 / 22.95
- Stock P/E N/A
- Book Value 7.94
- EPS -0.43
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.07 %
- 52 Week High 33.63
- 52 Week Low 13.80
About
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$19.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-18 | 2025-11-14 | 2025-08-13 | 2025-05-14 | 2025-03-27 | 2024-11-06 | 2024-08-13 | 2024-05-14 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-30 |
| Reported EPS | -0.8093 | -0.05 | 0.05 | -0.5883 | -0.2444 | -0.4229 | -0.8336 | 0.6514 | -1.04 | -1.8 | -2.6 | -0.1 |
| Estimated EPS | None | None | None | None | 0.74 | None | None | None | -1.4 | -2 | -2.6 | -0.14 |
| Surprise | 0 | 0 | 0 | 0 | -0.9844 | 0 | 0 | 0 | 0.36 | 0.2 | 0 | 0.04 |
| Surprise Percentage | None% | None% | None% | None% | -133.027% | None% | None% | None% | 25.7143% | 10% | 0% | 28.5714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPO
2026-07-17 11:39:52
This article announces a Form 4 filing for Precipio Inc., dated July 16, as reported by Investing.com. It is a brief notification with a link to regulatory details. The content also showcases various market data and other news headlines common to the Investing.com platform.
2026-07-16 20:10:34
Precipio, Inc. Director David Seth Cohen received 520 shares of common stock on July 15, 2026, as compensation for his Q2-26 board service, totaling $13K. This grant, valued at $25.24 per share, was issued in lieu of a cash payment and increased his direct holdings to 55,199 shares. The transaction was reported in a Form 4 filing and underscores a method of director compensation through equity.
2026-07-16 20:10:34
Precipio, Inc. director Jeffrey Cossman received a grant of 416 shares of common stock on July 15, 2026, as compensation for his Q2-26 Board of Directors service. This equity award, valued at $25.24 per share, increased his direct holdings to 16,549 common shares. The transaction was reported in a Form 4 filing and represents compensation in stock rather than cash for board service.
2026-07-16 20:10:34
Precipio, Inc. director Christina Rizopoulos received a grant of 108 shares of common stock on July 15, 2026, as compensation for her Board service during Q2-26. The shares were valued at $25.24 each and were issued in lieu of a cash payment. Following this transaction, Ms. Rizopoulos directly holds 5,628 Precipio common shares.
2026-07-12 08:40:51
This article analyzes Precipio Inc. (NASDAQ: PRPO) using AI models to provide trading strategies and a liquidity mapping report. It highlights strong sentiment across all horizons, suggesting an overweight bias, and details specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
2026-07-01 07:09:43
This article analyzes Precipio Inc. (NASDAQ: PRPO) stock, highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It identifies a mid-channel oscillation pattern and presents an exceptional 56.1:1 risk-reward setup, targeting a 16.3% gain. The piece also details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing specific entry, target, and stop-loss levels for different risk profiles.
